Trials / Unknown
UnknownNCT02577783
PDD vs PAD to Treat Initially Diagnosed MM
Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone | doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong) |
| DRUG | PAD regimen: bortizomib, dexamethasone and doxorubicin | doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong) |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2021-10-01
- Completion
- 2021-12-01
- First posted
- 2015-10-16
- Last updated
- 2020-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02577783. Inclusion in this directory is not an endorsement.